Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2010 May;51(3):448-50.
doi: 10.3349/ymj.2010.51.3.448.

Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient

Affiliations
Case Reports

Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient

Wonseok Kang et al. Yonsei Med J. 2010 May.

Abstract

Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma. Thalidomide, a drug with immunomodulating and antiangiogenic effects, has also shown promise as an effective treatment in multiple myeloma. Pulmonary complications are believed to be rare, especially interstitial lung disease. Here, we describe a patient with dyspnea and diffuse pulmonary infiltrates while receiving bortezomib and thalidomide in combination with dexamethasone for treatment-naïve multiple myeloma. Bronchoalveolar lavage demonstrated a significant decrease in the ratio of CD4 : CD8 T lymphocytes (CD4/8 ratio, 0.54). Extensive workup for other causes, including infections, was negative. A lung biopsy under video-assisted thorascopic surgery revealed a diagnosis of nonspecific interstitial pneumonitis. The symptoms and imaging study findings improved after initiating steroid treatment. Physicians should be aware of this potential complication in patients receiving the novel molecular-targeted antineoplastic agents, bortezomib and thalidomide, who present with dyspnea and new pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflicts of interest.

Figures

Fig. 1
Fig. 1
Chest CT scans. (A and B) After the first cycle of triple regimen, at the time of clinical deterioration demonstrating newly developed subpleural reticulation and diffuse interstitial changes in both upper and mid-lungs with a ground glass appearance. (C and D) Six weeks after initiating the steroid treatment with marked improvement of interstitial pneumonitis.
Fig. 2
Fig. 2
Video-assisted thoracoscopic lung biopsy photomicrographs (Hematoxylin Eosin staining). (A) Alveolar walls are thickened with diffuse interstitial fibrosis (original magnification ×12). (B) Interstitial fibrosis with characteristic temporal monogeneity is present with associated chronic interstitial inflammation, whereas fibroblastic foci are not seen (original magnification ×100).

References

    1. Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, et al. Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs. 2007;12:155–163. - PubMed
    1. Richardson PG, Hideshima T, Mitsiades C, Anderson KC. The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw. 2007;5:149–162. - PubMed
    1. Colson K, Doss DS, Swift R, Tariman J, Thomas TE. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs. 2004;8:473–480. - PubMed
    1. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006;17:372–379. - PubMed
    1. Onozawa M, Hashino S, Sogabe S, Haneda M, Horimoto H, Izumiyama K, et al. Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis. J Clin Oncol. 2005;23:2425–2426. - PubMed

Publication types